Synapse - Neha Korde

Results (226)

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

Journal Article

Manasanch, E. E.; Fernández de Larrea, C.; Zingone, A.; Steinberg, S. M.; Kwok, M.; Tageja, N.; Bhutani, M.; Kazandjian, D.; Roschewski, M.; Wu, P.; more...
Leukemia and Lymphoma (2017)

Fulltext@MSK | Save

Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients

Meeting Abstract

Mailankody, S.; Korde, N.; Roschewski, M. J.; Christofferson, A.; Boateng, M.; Zhang, Y.; Manasanch, E. E.; Kazandjian, D. G.; Kwok, M.; Bhutani, M.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Dietary pattern and risk of monoclonal gammopathy of undetermined significance: A population-based study

Meeting Abstract

Thordardottir, M.; Lindqvist, E. K.; Lund, S. H.; Costello, R.; Torfadottir, J. E.; Birgisdottir, B. E.; Burton, D.; Steingrimsdottir, L.; Korde, N. S.; Mailankody, S.; more...
Blood (2016)

Fulltext@MSK | Save

Risk of progression in monoclonal gammopathy of undetermined significance (MGUS): Results from a population-based screening study

Meeting Abstract

Lindqvist, E. K.; Lund, S. H.; Costello, R.; Burton, D.; Korde, N. S.; Mailankody, S.; Björkholm, M.; Eiriksdottir, G.; Launer, L. J.; Harris, T. B.; more...
Blood (2016)

Fulltext@MSK | Save

Whole exome sequencing from nine independent sites of extraosseous disease in a single patient with relapsed multiple myeloma show that extramedullary disease arise through a combination of branched and parallel evolution

Meeting Abstract

Landau, H.; Fan, J.; Giralt, S. A.; Peled, J. U.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Korde, N. S.; Mailankody, S.; Chung, D. J.; more...
Blood (2016)

Fulltext@MSK | Save

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R): Updated results of a phase 2 study

Meeting Abstract

Kazandjian, D.; Korde, N. S.; Roschewski, M.; Mailankody, S.; Morrison, C.; Manasanch, E. E.; Kwok, M. L.; Tageja, N.; Bhutani, M.; Zingone, A.; more...
Blood (2016)

Fulltext@MSK | Save

Longitudinal (18)f-FDG-PET-CT analysis in newly diagnosed multiple myeloma (NDMM) patients following carfilzomib, lenalidomide, dexamethasone induction and lenalidomide maintenance (CRd-R)

Meeting Abstract

Korde, N. S.; Kazandjian, D.; Roschewski, M.; Mailankody, S.; Hultcrantz, M.; Yuan, C. M.; Stetler-Stevenson, M.; Choyke, P.; Hassoun, H.; Lesokhin, A. M.; more...
Blood (2016)

Fulltext@MSK | Save

Sustained high rates of complete response and minimal residual disease negativity after 8 cycles of carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R) in patients with high-risk smoldering multiple myeloma: Updated results of clinical and correlative phase 2 study